Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10542 in Primary Immunoglobulin A (IgA) Nephropathy
NCT07474636Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10542 in immunoglobulin A nephropathy (IgAN), sponsored by Hansoh Pharmaceutical Group. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HS-10542
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07474636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474636.